Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 2/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397004 | 0.73 | TNK2 (0.39) | F2PRSS1LMNASMN1; SMN2HPGD | |
| SCHEMBL16625040 | 0.73 | TNK2 (0.39) | F2PRSS1LMNASMN1; SMN2HPGD | |
| SCHEMBL27651131 | 0.71 | CARM1 (0.38) | TSHRF2PRSS1SMN1; SMN2MAPT | |
| SCHEMBL5058681 | 0.70 | HTT (0.31) | TSHRHTT | |
| SCHEMBL28160957 | 0.70 | SLC6A2 (0.40) | — | |
| SCHEMBL11334997 | 0.70 | F2 (0.31) | F2PRSS1 | |
| SCHEMBL28538592 | 0.67 | DDB1 (0.40) | DDB1CRBN | |
| SCHEMBL14707885 | 0.67 | NPC1 (0.40) | TSHRF2PRSS1 | |
| SCHEMBL27332551 | 0.67 | CHRM2 (0.33) | — | |
| SCHEMBL809471 | 0.66 | DDB1 (0.45) | F2PRSS1SMN1; SMN2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581546-B1 | AVERMECTIN B1 DERIVATIVES HAVING AN ALKOXYMETHYL SUBSTITUENT IN THE 4''- OR 4'-POSITION | MERIAL INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-8263566-B2 | Avermectin B1 and avermectin B1 monosaccharide derivatives having an alkoxymethyl substituent in the 4″-or 4′-position | MERIAL LIMITED (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110230429-A1 | AVERMECTIN B1 AND AVERMECTIN B1 MONOSACCHARIDE DERIVATIVES HAVING AN ALKOXYMETHYL SUBSTITUENT IN THE 4\"-OR 4'-POSITION | SYNGENTA CROP PROTECTION, LLC (US) | 2011-09-22 | — | — | US | disclosed |
| US-8017589-B2 | Avermectin B1 and avermectin B1 monosaccharide derivatives having an alkoxymethyl substituent in the 4″-or 4′-position | SYNGENTA CROP PROTECTION LLC (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100210574-A1 | AVERMECTIN B1 AND AVERMECTIN B1 MONOSACCHARIDE DERIVATIVES HAVING AN ALKOXYMETHYL SUBSTITUENT IN THE 4\"-OR 4'-POSITION | SYNGENTA CROP PROTECTION, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-7737261-B2 | Avermectin B1 and avermectin B1 monosaccharide derivatives having an alkoxymethyl substituent in the 4″ -or 4′-position | SYNGENTA CORP PROTECTION, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20060148729-A1 | Avermectin b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substitutent in the 4\"-or 4'-position | MERIAL LIMITED | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210574-A1 | AVERMECTIN B1 AND AVERMECTIN B1 MONOSACCHARIDE DERIVATIVES HAVING AN ALKOXYMETHYL SUBSTITUENT IN THE 4\"-OR 4'-POSITION | CHRM1, CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TSHR 28/4885F2 3380/4885PRSS1 1353/4885 |
| US-20060148729-A1 | Avermectin b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substitutent in the 4\"-or 4'-position | CHRM2, CHRM1, CHRM4 | TSHR 16/4885F2 3676/4885PRSS1 1576/4885 |
| US-20110230429-A1 | AVERMECTIN B1 AND AVERMECTIN B1 MONOSACCHARIDE DERIVATIVES HAVING AN ALKOXYMETHYL SUBSTITUENT IN THE 4\"-OR 4'-POSITION | CHRM1, CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TSHR 28/4885F2 3380/4885PRSS1 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.